Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD4054 plus pemetrexed versus pemetrexed alone in previously treated non-squamous NSCLC
2007-007623-40Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Zibotentan plus pemetrexed with Placebo plus pemetrexed (2 arms). Primary endpoint: Time to death. Started Apr 2008; status: active.
02
Drugs
zibotentanpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-007623-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007623-40.